REMINDER: Our user survey closes on Friday, please submit your responses here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
0 0 0
JOIN UP THE DOTS!!! Gla ;-)
Lamellar's Director appointed to the BoD of Motif, confirmed today....RTO into Lamellar looks like a dead cert imho....and Iclaprim, already cleared Phase 11 patient trials, and held up by the FDA at end of Phase 111 patient trials because of toxicity concerns from the intravenously administered drug, they wanted another Phase 111 trial that Motif couldn't afford, and now looks like Lamellar's nebulised inhaler technology's lead compound for the treatment of lung damage in Covid-19 patients could be Iclaprim, which can go straight into patient trials, cutting costs and time and saving Lamellar £10's of millions in its development. Gla holders Fill Ya Boots!!!:-)
1/5/19
Motif Bio Signs Agreement with Lamellar Biomedical
Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections
Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Lamellar Biomedical Limited (Lamellar) under which Motif Bio will conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar's patented LAMELLASOME(TM) technology.
Iclaprim has been granted U.S. orphan drug designation for Staphylococcus aureus pneumonia in patients with Cystic Fibrosis (CF). Lamellar's LAMELLASOME(TM) candidate LMS-611, which has mucokinetic (mucus clearing) properties, has demonstrated antibiotic potentiation (the enhancement of certain properties of antibiotics) and has European orphan drug designation for CF.
The companies believe that, based on pre-clinical data with the two individual components, the combination could be a promising potential treatment for lung infections in patients with CF.
Dr. Graham Lumsden, Chief Executive Officer of Motif Bio, said: "We have been looking for a way to optimise the development of iclaprim in patients with CF. We are excited about the preliminary data we have seen with Lamellar's technology and look forward to evaluating it in combination with iclaprim."
Dr. Alex McLean, Chief Executive Officer of Lamellar Biomedical, said: "CF is a key area of interest for Lamellar. We are delighted to announce this partnership with Motif Bio, which will evaluate the antibiotic potentiation properties of our LAMELLASOME(TM) technology in combination with iclaprim. This collaboration augments our own work in this orphan indication, which is focused on a novel nucleic acid-based therapeutic, as we strive to develop a range of highly effective treatment options for patients with CF."
You purchased a million @0 30 and you want more profit !!!FFS
I invested here years ago. Well done today if you took a punt why not. It was a promising cure for sure.
Maybe a treatment for covid 19.
From rns in the past :
The Company also has plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication. A Phase 2 trial in patients with HABP has been successfully completed and a Phase 3 trial is being planned. Additionally, iclaprim has been granted orphan drug designation by the FDA for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis and is in preclinical development for this indication
This is a covid 19 play with a possible RTO of Lamellar. Read the RNS then DYOR.
It's just all the orders being being completed.
they also had some lung condition applications in the iclaprim pipeline and that was what Lamellar wanted to take a look at it for a year ago.
I brought close to a million shares this morning for 0.3 just for the craic as genedrive was making me so much money and I read some of the comments you all posted. What the hell happened today? I near crapped my self when I looked at close of trade? Does this have more legs?
Fully expecting that fella. Big day tomorrow
This almost worthless company does so stupid rises.
Well done to those who benefited from this!
Correct, but still confident
Why has this risen,
this could still go higher tomorrow morning, again.
@reece - yes , as someone who has followed this share for several years I think lots of people are going to lose lots of their investment. lunacy.
is this all because of RTO?? really?? £7m seems excessive
That’s UT so not a single buy (uncrossing trade)
Either someone knows something or that is the most idiotic buying ive ever witnessed in 13 years on lse
1.49 close...eventually. GLA for tomorrow.
From what I can tell, HSBC, Invesco, Peel Hunt and Bank of America still have holdings here
Hercules have 20% warrant options at a price of 0.42p
Does anyone know anything about the Holding situation of MTFB and what is free float?
Well that fills me with confidence for the morning
Looks like that 2.5 million at the end caused the jump
704% up...sheeeeesh kebab
At 1.49 Jesus wept
close
Look it is totally bonkers but could it be use for vivid 19?
Iclaprim supposed to be used for skin infections
iclaprim for treatment of patients with acute bacterial skin and skin structure infections ("ABSSSI").
This is a bit bonkers to say the least when I look at how much cash they have got, still well done all.